Glaxosmithkline Plc Stock Debt To Equity
| GSKN Stock | MXN 739.40 0.57 0.08% |
GlaxoSmithKline plc fundamentals help investors to digest information that contributes to GlaxoSmithKline Plc's financial success or failures. It also enables traders to predict the movement of GlaxoSmithKline Stock. The fundamental analysis module provides a way to measure GlaxoSmithKline Plc's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to GlaxoSmithKline Plc stock.
GlaxoSmithKline |
GlaxoSmithKline plc Company Debt To Equity Analysis
GlaxoSmithKline Plc's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current GlaxoSmithKline Plc Debt To Equity | 0.98 % |
Most of GlaxoSmithKline Plc's fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, GlaxoSmithKline plc is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
| Competition |
According to the company disclosure, GlaxoSmithKline plc has a Debt To Equity of 0.976%. This is 98.18% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—General industry. The debt to equity for all Mexico stocks is 98.0% higher than that of the company.
GlaxoSmithKline Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses GlaxoSmithKline Plc's direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of GlaxoSmithKline Plc could also be used in its relative valuation, which is a method of valuing GlaxoSmithKline Plc by comparing valuation metrics of similar companies.GlaxoSmithKline Plc is currently under evaluation in debt to equity category among its peers.
GlaxoSmithKline Fundamentals
| Return On Equity | 0.31 | |||
| Return On Asset | 0.0659 | |||
| Profit Margin | 0.51 % | |||
| Operating Margin | 0.25 % | |||
| Current Valuation | 1.79 T | |||
| Shares Outstanding | 2.05 B | |||
| Shares Owned By Insiders | 0.02 % | |||
| Shares Owned By Institutions | 14.10 % | |||
| Price To Earning | 11.33 X | |||
| Price To Book | 6.05 X | |||
| Price To Sales | 37.65 X | |||
| Revenue | 29.32 B | |||
| Gross Profit | 19.92 B | |||
| EBITDA | 8.8 B | |||
| Net Income | 14.96 B | |||
| Cash And Equivalents | 6.53 B | |||
| Cash Per Share | 0.32 X | |||
| Total Debt | 19.76 B | |||
| Debt To Equity | 0.98 % | |||
| Current Ratio | 1.43 X | |||
| Book Value Per Share | 5.25 X | |||
| Cash Flow From Operations | 7.4 B | |||
| Earnings Per Share | 49.71 X | |||
| Price To Earnings To Growth | 1.04 X | |||
| Number Of Employees | 45 | |||
| Beta | 0.28 | |||
| Market Capitalization | 1.38 T | |||
| Total Asset | 60.15 B | |||
| Retained Earnings | (3.7 B) | |||
| Working Capital | 1.91 B | |||
| Current Asset | 15.83 B | |||
| Current Liabilities | 13.92 B | |||
| Z Score | 41.4 | |||
| Annual Yield | 0.04 % | |||
| Five Year Return | 5.28 % | |||
| Net Asset | 60.15 B | |||
| Last Dividend Paid | 0.61 |
About GlaxoSmithKline Plc Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze GlaxoSmithKline plc's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of GlaxoSmithKline Plc using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of GlaxoSmithKline plc based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for GlaxoSmithKline Stock Analysis
When running GlaxoSmithKline Plc's price analysis, check to measure GlaxoSmithKline Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline Plc is operating at the current time. Most of GlaxoSmithKline Plc's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline Plc's price. Additionally, you may evaluate how the addition of GlaxoSmithKline Plc to your portfolios can decrease your overall portfolio volatility.